DNA News and Research

RSS

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Sunlight Research's report analyzes Amgen EPO US patent portfolio

Sunlight Research((TM)) - The Source for Patent Analysis today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Clinical Logistics partners with a GLP compliant laboratory

Clinical Logistics is pleased to announce the introduction of specimen storage services through a partnership with Gentris Corporation (Gentris), a GLP compliant laboratory, located in Morrisville, North Carolina.

13 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Biomarker Discovery Service from Arrayit to unravel mystery of genetic links for human disease states

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service.

11 Sep 2009

eChIP genetic technique developed to examine FA proteins with DNA crosslinks

While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.

11 Sep 2009

New study reveals that actual sex ratios can sway from the ideal

In a perfect world, for every boy there would of course be a girl, but a new study shows that actual sex ratios can sometimes sway very far from that ideal. In fact, the male-to-female ratio of one tropical butterfly has shifted rapidly over time and space, driven by a parasite that specifically kills males of the species, reveals a report published online on September 10th in Current Biology, a Cell Press publication.

11 Sep 2009

New Drug Application for trabectedin approved by the FDA

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.

11 Sep 2009

QIAGEN's new QIAsafe DNA blood products launched

Biomatrica, Inc. and QIAGEN announce the launch of QIAGEN's new QIAsafe DNA Blood Products, the first dry blood storage available on a matrix based on Biomatrica's innovative SampleMatrix(R) technology.

From QIAGEN Manchester Limited 10 Sep 2009

Complete Genomics sequences and delivers 14 human genomes

Complete Genomics Inc., a third-generation human genome sequencing company, announced today that it has sequenced, analyzed and delivered 14 human genomes to customers since March 2009.

10 Sep 2009

NIH renews second year of a 5-year licensing agreement with BIOBASE

BIOBASE, a leading provider of biological databases and software for the life sciences industry, announced today the renewal of the second year of a 5-year licensing agreement with the National Institutes of Health (NIH). This 5-year contract provides all 27 NIH institutions with locally installed access to the BIOBASE Knowledge Library™ which includes the premier TRANSFAC® and PROTEOME® databases.

10 Sep 2009

Research on the role of microRNAs in cellular processes

RNAs, serving as a mere intermediary between DNA and proteins, were long regarded as a poor relation by researchers, attracting little interest. However, following the discovery of small RNAs known as microRNAs, they have increasingly been moving into the limelight. MicroRNAs bind to messenger RNA (mRNA), thereby regulating the translation of genes into proteins.

10 Sep 2009

Research reveals genetic conversation between X and Y chromosomes

In the week that the University of Leicester celebrates the 25th anniversary of the discovery of DNA fingerprinting (Thursday September 10) new findings from the world-renowned University of Leicester Department of Genetics reveal for the first time that the male and female do truly communicate -at least at the fundamental genetic level.

10 Sep 2009

New Influenza A/H1N1 detection kit launched

QIAGEN, today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance of the swine flu pandemic. QIAGEN’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes “swine flu”, as well as of all other known Influenza A and B virus strains.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Three genes linked to Lou Gehrig's disease

Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease.

10 Sep 2009

Promega unveils Maxwell 16 Viral Total Nucleic Acid Purification Kit

Promega announces the release of the Maxwell 16 Viral Total Nucleic Acid Purification Kit which, among other labs, currently serves the OCA Hospital in Mexico for H1N1 clinical research.

10 Sep 2009

Yeast mutants may yield new opportunities for anticancer drug development

Until now, the mode of action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to relieve bone pain and to prevent skeletal complications in bone metastasis, has been almost entirely unknown. Researchers writing in BioMed Central's open access journal Genome Biology have used 'barcoded' yeast mutants to identify new biological processes involved in the cellular response to N-BPs, opening up opportunities for the development of new anticancer drugs.

10 Sep 2009

Cepheid's Flu Panel test to provide 45-minute identification of Flu A infection

Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.

9 Sep 2009